MELVILLE, N.Y.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based products and therapies for various personal medical applications, announced that it will be presenting at The Brewer Group’s (“TBG”) inaugural Innovations Conference in Miami on Monday, February 9, 2015 at The Mondrian South Beach.
Between 3:30-4:00pm EST, BRT’s CEO, Mark Weinreb, will be presenting the Company’s pioneering stem cell initiatives including brtxDISC™, its lead therapeutic product to be used in an investigational non-surgical treatment of chronic lumbar disc disease, and ThermoStem®, which is a treatment under development that uses brown fat stem cells for metabolic disorders. The Company recently announced a successful pre-investigational new drug (Pre-IND) meeting with the FDA for brtxDISC™.
The Brewer Group Innovations Conference represents an opportunity for small cap, middle market, and emerging public and private companies to showcase their products, services, and programs. The event will provide an intimate, exclusive platform to bring experts, investors, and companies together to help identify and facilitate opportunities and strategic partnerships.
For more information on the TBG Innovations Conference or to request an invitation to attend, please visit www.thebrewergroup.com/innovations.
About The Brewer Group The Brewer Group, Inc. (TBG) is an industry agnostic holding company with assets ranging numerous sectors. TBG’s relationships with key international decision makers spanning government development agencies, financial institutions, multinational corporations, NGO’s and numerous leaders in sports and entertainment place TBG in a unique position to grow its portfolio. TBG takes pride in identifying companies whose goal is to make a social impact on the communities in which they serve. For further information, please visit www.thebrewergroup.com.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells, including:
- brtxDISC™ (Disc Implanted Stem Cells), BRT’s lead therapeutic product, is a mesenchymal stem cell product derived from autologous human bone marrow. It is to be used in an investigational non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease and is intended for patients whose pain has not been alleviated by non-invasive procedures and potentially face the prospect of surgery. The treatment, utilizing brtxDISC™, involves culturing a patient’s own stem cells and then delivering them to the damaged disc in an outpatient procedure.
- ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forwardlooking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.